DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS

被引：0

作者：

Hall, J. ^{[1
]}

Khela, K. ^{[1
]}

Bertwistle, D. ^{[2
]}

Xiao, H. ^{[3
]}

机构：

[1] Adelphi Real World, Bollington, England

[2] Bristol Myers Squibb, Uxbridge, Middx, England

[3] Bristol Myers Squibb, Lawrence Township, NJ USA

来源：

VALUE IN HEALTH | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN340

引用

页码：S482 / S483

页数：2

共 50 条

[1] The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
Hall, J. P.
Khela, K.
Moon, R.
Middleton-Dalby, C.
Bertwistle, D.
Xiao, H.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S918 - S918
[2] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
Hall, J.
Khela, K.
Middleton-Dalby, C.
Bertwistle, D.
Xiao, H.
[J]. VALUE IN HEALTH, 2020, 23 : S485 - S485
[3] Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.
Kelly, Ronan Joseph
Le, Hannah
Wu, Sze-Jung
Laurie, Melissa
Raval, Amit D.
Shi, Qian
Korytowsky, Beata
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Impact on work productivity in unresectable locally advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma patients and their caregivers
Xiao, H.
Hall, J. P.
Khela, K.
Moon, R.
Bertwistle, D.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S904 - S904
[5] Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.
Gardeazabal, Itziar
Hierro, Cinta
Viaplana, Cristina
Nuciforo, Paolo
Vivancos, Ana
Mercade, Teresa Macarulla
Garralda, Elena
Eugenia Semidey, Maria
Grau Bejar, Juan Francisco
Dienstmann, Rodrigo
Landolfi, Stefania
Alsina, Maria
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] REAL-WORLD (RW) UNITED STATES (US) FIRST-LINE (1L) TREATMENT (TX) PATTERNS AND OVERALL SURVIVAL (OS) OF PATIENTS (PTS) WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER, GASTROESOPHAGEAL JUNCTION CANCER AND ESOPHAGEAL ADENOCARCINOMA (GC/GEJC/EAC) BY HER2+/- STATUS
Xiao, H.
You, M.
Zhang, Y.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S594 - S595
[7] Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).
Chau, Ian
Ayers, Dieter
Goring, Sarah
Keeping, Sam
Goulding, Rebecca
Cope, Shannon
Chamot, Eric
Le, Hannah
Xu, Yanqing
Abraham, Pranav
Korytowsky, Beata
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[8] What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).
Le, Dung T.
Janjigian, Yelena Yuriy
Ott, Patrick Alexander
Korytowsky, Beata
Le, Hannah
Trong Kim Le
Zhang, Ying
Maglinte, Gregory
Patel, Dhiren
Shangguan, Tong
Chau, Ian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
Chen, Zhendong
Bai, Yuxian
Zhang, Tao
Ying, Jieer
Lin, Xiaoyan
Yang, Liu
Wang, Jun
Zhang, Juan
Yu, Fan
Fei, Cong
Huang, Ruiqi
Li, Jin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
Virik, Kiran
Wilson, Robert B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →